The impact of treatment-resistant depression on health care utilization and costs

Journal of Clinical Psychiatry

Volumn 63, Issue 11, 2002, Pages 963-971

  Crown, William H ^a   Finkelstein, Stan ^b   Berndt, Ernst R ^b   Ling, Davina ^a   Poret, Amy W ^a   Rush, A John ^c   Russell, James M ^d  

^a MEDSTAT GROUP   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR DEPRESSION; CONTROLLED STUDY; DATA BASE; ELECTROCONVULSIVE THERAPY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTIVARIATE ANALYSIS; OUTPATIENT CARE; PERSONALITY DISORDER; PHARMACEUTICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUBSTANCE ABUSE; SUICIDE ATTEMPT;

EID: 0036855307     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v63n1102     Document Type: Article

References (32)

1. Fava M. Management of nonresponse and intolerance: Switching strategies. J Clin Psychiatry 2000;61(suppl 2):10-12
2. Zajecka JM. Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry 2000;61 (suppl 2):20-25
3. Melfi C, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998;55:1128-1132
4. Feiger AD, Bielski RJ, Bremmer J, et al. Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. Int Clin Psychopharmacol 1999;14:1-28
5. Sajatovic M, DiGiovanni S, Fuller M, et al. Nefazodone therapy in patients with treatment-resistant or treatment-intolerant depression and high psychiatric comorbidity. Clin Ther 1999;21:733-740
6. Kocsis J. New strategies for treating chronic depression. J Clin Psychiatry 2000;60(suppl 11):42-45
7. Agosti V. One year clinical and psychosocial outcomes of early-onset chronic depression. J Affect Disord 1999;54:171-175
8. Nelson JC. Treatment of antidepressant nonresponders: Augmentation or switch? J Clin Psychiatry 1998;59(suppl 15):35-41
9. Delgado PL. Approaches to the enhancement of patient adherence to antidepressant medication treatment. J Clin Psychiatry 2000;61(suppl 2):6-9
10. Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Arch Gen Psychiatry 1984;41:1096-1104
11. Montgomery SA, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 1988;153:69-73
12. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47:1093-1099
13. Frank E, Kupfer DJ, Perel JM. Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord 1993;27:139-145
14. Entsuah AR, Rudolph RL, Hackett D, et al. Efficacy of venlafaxine and placebo during long-term treatment of depression: A pooled analysis of relapse rates. Int Clin Psychopharmacol 1996;11:137-145
15. Byrne SE, Rothschild AJ. Loss of antidepressant efficacy during maintenance therapy: Possible mechanisms and treatments. J Clin Psychiatry 1998;59:279-288
16. Schmidt ME, Fava M, Robinson JM, et al. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. J Clin Psychiatry 2000;61:851-857
17. Mitchell PB, Schweitzer I, Burrows G, et al. Efficacy of venlafaxine and predictors of response in a prospective open-label study of patients with treatment-resistant major depression. J Clin Psychopharmacol 2000;20:483-487
18. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression: Double-blind, randomized comparison. Br J Psychiatry 1999;175:12-16
19. Nierenberg AA, Feighner JP, Rudolph R, et al. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:419-423
20. Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342:1462-1470
21. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-134
22. Rosenbaum JF, Fava M, Nierenberg AA, et al. Treatment-resistant mood disorders. In: Treatments of Psychiatric Disorders, Vol 1. 3rd Ed. Washington, DC: American Psychiatric Press; 2001:1307-1388
23. Fawcett J. Compliance: Definitions and key issues. J Clin Psychiatry 1995;56(suppl 1):4-10
24. Kaplan EM. Antidepressant noncompliance as a factor in the discontinuation syndrome. J Clin Psychiatry 1997;58(suppl 7):31-36
25. Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity and levels of psychopathology in major depression: A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992;49:809-816
26. Sackeim HA, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: Efficacy, side-effects, and predictors of outcome. Neuropsychopharmacology 2001;25:713-728
27. Sackeim HA, Prudic J, Devanand DP, et al. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol 1990;10:96-104
28. U.S. Bureau of Labor, Bureau of Statistics. Consumer Price Index (Chapter 17). In: Bureau of Labor Statistics Handbook of Methods. Washington, DC: US Bureau of Labor Statistics; 1997. Available at: http://www.bls.gov/opub/hom/homch17_a.htm
29. Lane R, McDonald G. Reducing the economic burden of depression. Int Clin Psychopharmacol 1994;9:229-243
30. Rosenbaum JF, Hylan TR. Cost of depressive disorders. In: The World Psychiatric Association's Series, Evidence and Experience in Psychiatry, vol 1. Chichester, UK: John Wiley & Sons; 1999
31. Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
32. Guy W. ECDEU Assessment Manual for Psychoparmacology. US Dept Health, Education, & Welfare. Washington, DC: National Institute of Mental Health; 1995:73-88